Welcome to our dedicated page for CYTOKINETICS SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics, Inc. director Nancy Wysenski reported an acquisition of company stock as equity compensation. On July 15, 2026, she received 75 shares of Common Stock as a fully vested grant under the Cytokinetics Equity in lieu of Cash Retainer Program at an indicated value of $82.6200 per share. Following this grant, she directly holds 33,992 shares of Cytokinetics common stock.
WIERENGA WENDELL reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc. director Wendell Wierenga received a grant of 75 shares of common stock on July 15, 2026, at $82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 35,563 shares.
Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director Edward M. Kaye, MD received a grant of 151 shares of common stock on July 15, 2026 under the Cytokinetics Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 10,434 common shares.
HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director John T. Henderson received a grant of 272 shares of common stock on 2026-07-15 at 82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested, bringing his direct holdings to 78,360 shares and indirect spouse-held holdings to 83 shares.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director Harrington Robert Arthur received a grant of 151 shares of common stock on July 15, 2026, under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant, bringing his direct holdings to 21,932 shares.
Daly James M reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director James M. Daly received a grant of 151 shares of Common Stock on 2026-07-15 under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant and increase his directly held position to 3,390 shares.
Cytokinetics Inc President & CEO Robert I. Blum exercised non-qualified stock options for 7,490 shares of common stock at $10.60 per share and, on the same date, sold a total of 7,500 shares at $82.02 per share in open-market transactions, leaving 377,820 shares held directly and 2,083 shares held indirectly by each of two irrevocable trusts.
FMR LLC reports beneficial ownership of 5,248,579.71 shares of Cytokinetics Inc. Common Stock, representing 3.9% of the class as of 06/30/2026. The filing (Amendment No. 8 to Schedule 13G/A) lists sole dispositive power for 5,248,579.71 shares and sole voting power of 5,220,899.42 shares. The report notes that one or more other persons may have rights to dividends or sale proceeds but that no other person holds more than 5% of the outstanding common stock. The filing is signed under a power of attorney and references an exhibit for a 13d-1(k)(1) agreement.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an exercise-and-sale transaction in company stock. He sold 3,500 shares of common stock in an open-market sale at $86.62 per share and exercised options to acquire 3,500 shares at $7.80 per share. Following these transactions, he directly holds 153,902 shares of common stock and 37,386 non-qualified stock options.
CYTK submitted a Form 144 notice to sell 24,500 shares of Common Stock via exercise of stock options, dated 07/07/2026, with sale method listed as Cash. The filing also lists five prior 10b5-1 sales of 3,500 shares each in April–June 2026.